Levation Pharma

Executive Summary

Levation Pharma is a private Israeli-American biotechnology company developing LEV-102, a novel non-surgical treatment for acquired blepharoptosis (droopy eyelid). The product is an odorless, colorless aqueous gel that delivers oxymetazoline to the upper eyelid, stimulating Mueller’s muscle to lift the lid without surgery. The company is currently advancing LEV-102 through a Phase I/II clinical trial in the United States, targeting a large and underserved patient population seeking an alternative to surgical correction. Founded in 2020 and headquartered in Jerusalem, Levation Pharma operates with a lean team of 10-50 employees and has not disclosed total funding or valuation. Levation Pharma’s early-stage status and focused pipeline present both opportunity and risk. The successful completion of its Phase I/II trial and subsequent data readout would be a critical milestone, potentially de-risking the asset and attracting partnership or financing interest. However, as a private company with limited public information, visibility into its financial runway and operational timeline is constrained. The conviction score reflects the promise of a non-surgical solution in ophthalmology tempered by the high failure rate of early-stage biotech trials. Near-term catalysts will be pivotal in determining the company's trajectory.

Upcoming Catalysts (preview)

• Q1 2027Phase I/II top-line data readout40% success
• Q3 2027Partnership or licensing deal for LEV-10230% success
• Q2 2027Series A or B financing round50% success